16:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Nov. 14 decision that invalidated second medical use patent...
23:32 , Nov 14, 2018 |  BC Extra  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims...
07:00 , May 18, 2015 |  BC Week In Review  |  Company News

Actavis, TPG Capital deal

Actavis completed the divestiture of its Aptalis Pharmaceutical Technologies subsidiary to private investment firm TPG for an undisclosed sum. Aptalis said that its new name is Adare Pharmaceuticals (see BioCentury, Feb. 16). Actavis Group ,...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Actavis, TPG Capital deal

Actavis will divest its Aptalis Pharmaceutical Technologies outsourcing and R&D business to private investment firm TPG for an undisclosed sum. The deal is expected to close by mid-year. Actavis said the move will allow it...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Dalbavancin: SPA received

Durata said it received an SPA from FDA for a Phase III trial to compare a single dose of 1,500 mg IV Dalvance plus a single dose of IV azithromycin vs. linezolid plus azithromycin in...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Durata Therapeutics, Actavis deal

Actavis will acquire Durata for $23 per share in cash up front, or $675 million, plus up to $146.5 million in regulatory and commercial milestones in the form of a contingent value right (CVR) worth...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

HRA Pharma, Afaxys Inc. sales and marketing update

The Afaxys Pharmaceuticals division of Afaxys relaunched emergency contraceptive ella ulipristal acetate in the U.S. Afaxys has exclusive U.S. commercialization rights to the product from HRA Pharma. Afaxys declined to disclose details, and HRA Pharma...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Fibristal ulipristal acetate regulatory update

Actavis said Health Canada approved Fibristal ulipristal acetate to treat moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The company plans to launch...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

MoxDuo IR morphine/oxycodone regulatory update

QRxPharma said it will resubmit an NDA this quarter for MoxDuo IR (12 mg morphine/8 mg oxycodone) to manage acute pain following clarification with FDA on the necessary steps for approval. The company expects a...
08:00 , Dec 17, 2012 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/14 cls Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Roth Capital Partners Scott Henry New Buy 13% $5.84 Henry set a $10 target ahead of the Dec....